Skip to main content
NCBI home page
Canadian Family Physician logoLink to Canadian Family Physician
. 1991 Jun;37:1469–1477.

Contemporary Management of Bladder Cancer

Identifying patients who are at risk

David Bell, Yves Fradet
PMCID: PMC2145394  PMID: 21229043

Abstract

Bladder cancer is currently the fifth most common cancer in Western society, and its incidence appears to be increasing. Important advances have recently occurred in both diagnostic and therapeutic approaches to bladder neoplasms. Presentation is not unique, and physician awareness is important to identify patients who are at risk for bladder neoplasia and consequently require further investigation. A diagnostic approach and contemporary management are discussed.

Full text

PDF
1469

Images in this article

1471Figure 1
on p.1471
1474Figure 4
on p.1474

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ahlering T. E., Weinberg A. C., Razor B. A comparative study of the ileal conduit, Kock pouch and modified Indiana pouch. J Urol. 1989 Nov;142(5):1193–1196. doi: 10.1016/s0022-5347(17)39026-2. [DOI] [PubMed] [Google Scholar]
  2. Benson R. C., Jr Treatment of diffuse transitional cell carcinoma in situ by whole bladder hematoporphyrin derivative photodynamic therapy. J Urol. 1985 Oct;134(4):675–678. doi: 10.1016/s0022-5347(17)47379-4. [DOI] [PubMed] [Google Scholar]
  3. Fradet Y. Biological markers of prognosis in invasive bladder cancer. Semin Oncol. 1990 Oct;17(5):533–543. [PubMed] [Google Scholar]
  4. Fradet Y., Islam N., Boucher L., Parent-Vaugeois C., Tardif M. Polymorphic expression of a human superficial bladder tumor antigen defined by mouse monoclonal antibodies. Proc Natl Acad Sci U S A. 1987 Oct;84(20):7227–7231. doi: 10.1073/pnas.84.20.7227. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Fradet Y., Tardif M., Bourget L., Robert J. Clinical cancer progression in urinary bladder tumors evaluated by multiparameter flow cytometry with monoclonal antibodies. Laval University Urology Group. Cancer Res. 1990 Jan 15;50(2):432–437. [PubMed] [Google Scholar]
  6. Heney N. M., Ahmed S., Flanagan M. J., Frable W., Corder M. P., Hafermann M. D., Hawkins I. R. Superficial bladder cancer: progression and recurrence. J Urol. 1983 Dec;130(6):1083–1086. doi: 10.1016/s0022-5347(17)51695-x. [DOI] [PubMed] [Google Scholar]
  7. Morales A., Eidinger D., Bruce A. W. Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol. 1976 Aug;116(2):180–183. doi: 10.1016/s0022-5347(17)58737-6. [DOI] [PubMed] [Google Scholar]
  8. Orihuela E., Herr H. W., Pinsky C. M., Whitmore W. F., Jr Toxicity of intravesical BCG and its management in patients with superficial bladder tumors. Cancer. 1987 Aug 1;60(3):326–333. doi: 10.1002/1097-0142(19870801)60:3<326::aid-cncr2820600309>3.0.co;2-5. [DOI] [PubMed] [Google Scholar]
  9. Prout G. R., Jr, Lin C. W., Benson R., Jr, Nseyo U. O., Daly J. J., Griffin P. P., Kinsey J., Tian M. E., Lao Y. H., Mian Y. Z. Photodynamic therapy with hematoporphyrin derivative in the treatment of superficial transitional-cell carcinoma of the bladder. N Engl J Med. 1987 Nov 12;317(20):1251–1255. doi: 10.1056/NEJM198711123172003. [DOI] [PubMed] [Google Scholar]
  10. Sarosdy M. F., Lamm D. L. Long-term results of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer. J Urol. 1989 Sep;142(3):719–722. doi: 10.1016/s0022-5347(17)38865-1. [DOI] [PubMed] [Google Scholar]
  11. Scher H. I. Chemotherapy for invasive bladder cancer: neoadjuvant versus adjuvant. Semin Oncol. 1990 Oct;17(5):555–565. [PubMed] [Google Scholar]
  12. Silverberg E., Boring C. C., Squires T. S. Cancer statistics, 1990. CA Cancer J Clin. 1990 Jan-Feb;40(1):9–26. [PubMed] [Google Scholar]
  13. Sternberg C. N., Yagoda A., Scher H. I., Watson R. C., Herr H. W., Morse M. J., Sogani P. C., Vaughan E. D., Jr, Bander N., Weiselberg L. R. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium. J Urol. 1988 Mar;139(3):461–469. doi: 10.1016/s0022-5347(17)42494-3. [DOI] [PubMed] [Google Scholar]
  14. Studer U. E., Ackermann D., Casanova G. A., Zingg E. J. A newer form of bladder substitute based on historical perspectives. Semin Urol. 1988 Feb;6(1):57–65. [PubMed] [Google Scholar]
  15. Thompson I. M., Peek M., Rodriguez F. R. The impact of cigarette smoking on stage, grade and number of recurrences of transitional cell carcinoma of the bladder. J Urol. 1987 Mar;137(3):401–403. doi: 10.1016/s0022-5347(17)44048-1. [DOI] [PubMed] [Google Scholar]
  16. Torti F. M., Lum B. L. The biology and treatment of superficial bladder cancer. J Clin Oncol. 1984 May;2(5):505–531. doi: 10.1200/JCO.1984.2.5.505. [DOI] [PubMed] [Google Scholar]

Articles from Canadian Family Physician are provided here courtesy of College of Family Physicians of Canada

RESOURCES